AGEN Logo

Agenus Inc. (AGEN) 

NASDAQ
Market Cap
$72.02M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
211 of 963
Rank in Industry
130 of 552

Largest Insider Buys in Sector

AGEN Stock Price History Chart

AGEN Stock Performance

About Agenus Inc.

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Insider Activity of Agenus Inc.

Over the last 12 months, insiders at Agenus Inc. have bought $324,050 and sold $0 worth of Agenus Inc. stock.

On average, over the past 5 years, insiders at Agenus Inc. have bought $171,525 and sold $1.46M worth of stock each year.

Highest buying activity among insiders over the last 12 months: ARMEN GARO H (See Remarks) — $648,100.

The last purchase of 500,000 shares for transaction amount of $324,050 was made by ARMEN GARO H (See Remarks) on 2024‑02‑15.

List of Insider Buy and Sell Transactions, Agenus Inc.

2024-02-15PurchaseSee Remarks
500,000
0.0915%
$0.65$324,050-48.74%
2023-11-15Purchasedirector
25,000
0.0067%
$0.76$19,000-20.20%
2022-01-06SaleChief Medical Officer
38,679
0.0149%
$3.06$118,346-16.94%
2021-09-13SaleChairman and CEO
82,107
0.0357%
$6.50$533,696-56.93%
2021-09-10SalePFO & PAO
11,120
0.0047%
$6.50$72,280-57.69%
2020-06-17Sale10 percent owner
283,840
0.1709%
$3.66$1.04M+4.04%
2020-06-16Sale10 percent owner
144,160
0.0877%
$3.66$528,015+4.63%
2020-06-15Sale10 percent owner
384,025
0.2247%
$3.57$1.37M+3.05%
2020-06-12Sale10 percent owner
9,100
0.0055%
$3.58$32,556+6.30%
2020-06-11Sale10 percent owner
183,875
0.1139%
$3.77$692,786+3.20%
2017-12-12SaleChief Legal Officer
16,716
0.0174%
$3.46$57,842-16.91%
2017-12-12SaleVP, Finance
11,220
0.0117%
$3.46$38,836-16.91%
2017-12-12SaleChief Commercial Officer
7,424
0.0077%
$3.46$25,691-16.91%
2017-12-12SaleChief Communications Officer
7,022
0.0073%
$3.46$24,304-16.91%
2017-12-12SaleChief Technology Officer
13,092
0.0137%
$3.46$45,302-16.91%
2017-10-30PurchaseChairman & CEO
80,776
0.0835%
$3.61$291,706-2.11%
2017-10-27PurchaseChairman & CEO
119,224
0.1159%
$3.51$418,524-5.18%
2017-04-12PurchaseChairman & CEO
58,912
0.0604%
$3.29$194,109+18.52%
2017-04-10PurchaseChairman & CEO
141,088
0.1464%
$3.37$474,930+16.21%
2017-02-14Purchase10 percent owner
20M
29.1662%
$6.00$120M-14.32%

Insider Historical Profitability

17.93%
ARMEN GARO HSee Remarks
625969
2.6684%
$3.07266+16.59%
INCYTE CORP10 percent owner
16972968
72.3519%
$3.0715<0.0001%
QVT Associates GP LLC10 percent owner
6915630
29.4798%
$3.0701
WIINBERG ULFdirector
124063
0.5289%
$3.0720<0.0001%
Valentine KarenChief Legal Officer
101521
0.4328%
$3.07015
KLASKIN CHRISTINE MPFO & PAO
93056
0.3967%
$3.07016
Sharp Shalinidirector
81311
0.3466%
$3.07215+24.13%
HATSOPOULOS JOHNdirector
65000
0.2771%
$3.0730+179.69%
O'Day Steven JChief Medical Officer
61321
0.2614%
$3.0701
Baysal OzerChief Commercial Officer
58790
0.2506%
$3.0711+35.69%
Wentworth KerryVP, Clinical, Reg & Qual
57410
0.2447%
$3.07016
Buell JenniferChief Communications Officer
35656
0.152%
$3.0701
Duncan AlexChief Technology Officer
21026
0.0896%
$3.0701
MARGARET EISENdirector
20000
0.0853%
$3.0720+21.26%
Ballantyne Charles EvanChief Financial Officer
10000
0.0426%
$3.0710<0.0001%
Wright Timothydirector
10000
0.0426%
$3.0710<0.0001%
Thornton PeterCFO & Sr. VP
5000
0.0213%
$3.0710+22.52%
SRIVASTAVA PRAMODdirector
1610
0.0069%
$3.0701
ATLEE FRANK V IIIdirector
0
0%
$3.0701
AFEYAN NOUBARdirector
0
0%
$3.0701
Malik Shahzaddirector
0
0%
$3.0702

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$19.95B163.8234.4M+13.66%+$2.4B0.37
Deep Track Capital Lp$18.38B150.9531.7M0%+$084.33
Point72 Asset Management$17.47B143.430.11M+151.26%+$10.51B25.54
BlackRock$16.96B139.2929.25M-9.27%-$1.73B0.37
Artal Group S A$9.07B74.4415.63M0%+$039.62
Geode Capital Management$4.7B38.578.1M+2.43%+$111.4M0.4
State Street$4.32B35.497.45M-14.15%-$712.19M0.18
Renaissance Technologies$3.14M25.795.42M-10.25%-$358,832.900.01
Goldman Sachs$38.11M15.643.29M+13.53%+$4.54M0.01
D. E. Shaw & Co.$1.9B15.623.28M+7.88%+$138.96M1.83
Northern Trust$1.83B15.053.16M-9.23%-$186.47M0.3
Millennium Management LLC$1.55B12.722.67M-68.14%-$3.31B1
Morgan Stanley$1.52B12.512.63M+1.5%+$22.45M0.11
Charles Schwab$1.41B11.62.44M-10.89%-$172.62M0.31
Wellington Management Company$1.33B10.942.3MNew+$1.33B0.23
BNY Mellon$804.12M6.61.39M-6.36%-$54.65M0.15
Bank of America$776.41M6.381.34M+0.08%+$593,919.040.08
Gsa Capital Partners Llp$737,000.006.051.27M-47.04%-$654,500.330.06
Panagora$712.71M5.851.23M+7.57%+$50.15M3.57
AQR Capital$689.81M5.661.19M+157.66%+$422.1M1.08
Nuveen$665.98M5.471.15M0%+$00.19
Oracle Investment Management Inc$618.84M5.081.07M-24.7%-$203M83.36
Wells Fargo$562.69M4.62970,150-4.06%-$23.84M0.15
Key Client Fiduciary Advisors Llc$498.2M4.09858,969New+$498.2M74.26
Acadian Asset Management$439,000.003.61757,397+1,959.93%+$417,688.65<0.01
Two Sigma$356.39M2.93614,463-48.93%-$341.45M0.54
Fidelity Investments$355.14M2.92612,313-1.89%-$6.85M0.02
Franklin Templeton Investments$318.77M2.62549,608+236.31%+$223.99M0.1
RhumbLine Advisers$317.03M2.6546,623+4.55%+$13.81M0.29
UBS$310.08M2.55534,621-7.72%-$25.94M0.09
Susquehanna International Group$303.35M2.49523,017-12.56%-$43.56M0.3
Exchange Traded Concepts, LLC$275.57M2.26475,130+343.97%+$213.5M6.26
Pennant Capital Management Llc$272.37M2.24469,6000%+$043.04
Tudor Investment Corp Et Al$217.86M1.79375,6270%+$02.33
Connor Clark & Lunn Investment Management Ltd$216.15M1.78372,671New+$216.15M0.47
T. Rowe Price$208,000.001.7357,915+52.4%+$71,514.37<0.0001
Voya Investment Management LLC$201.7M1.66347,764+18.94%+$32.12M0.22
Values First Advisors, Inc.$194.94M1.6336,100+24.56%+$38.44M43.19
State of Wisconsin Investment Board$175.97M1.45303,400+894.79%+$158.28M0.46
Barclays$167,000.001.38289,401-52.56%-$185,005.24<0.0001
Jane Street Capital$159.92M1.31275,730-75.62%-$496.15M0.15
AllianceBernstein$147.91M1.21255,0100%+$00.05
Powell Investment Advisors LLC$141.23M1.16243,500+21.75%+$25.23M42.82
CAPTRUST$129.29M1.06222,915+17.82%+$19.56M0.11
American International Group$108.93M0.89187,814-0.85%-$935,538.970.37
Los Angeles Capital Management LLC$101.66M0.84175,272-12.72%-$14.81M0.33
Deutsche Bank$96.83M0.8166,954-7.07%-$7.36M0.04
Group One Trading$96.46M0.79166,309-42.51%-$71.32M1.28
Invesco$91.56M0.75157,859+4.42%+$3.87M0.02
JPMorgan Chase$89.77M0.74154,778-38.6%-$56.44M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.